J&J: settlement agreement in opioid crisis
The $149.5 million settlement will be drawn from the nationwide settlement announced in 2021 and will support community efforts in the fight against the opioid crisis in Washington State.
The laboratory makes it clear that this settlement is not an admission of liability or wrongdoing, and that it will continue to defend itself against 'any litigation that the final agreement does not resolve'.
J&J also maintains that its actions related to the marketing and promotion of important opioid prescription drugs were 'appropriate and responsible', and that sales of Duragesic, Nucynta and Nycynta ER represented less than 1% of total opioid prescriptions in Washington State and the US since their launch.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction